Science & Technology
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R42HL164300-02
Award Ceiling
$1.6M
Award Floor
$1.6M
Close Date
Aug 31, 2025
Total Funding
$1.6M
Expected Awards
1
Posted Date
Sep 19, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-4R42HL164300-02
Description
STTR Phase Phase II award: "Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension" awarded to AQUALUNG THERAPEUTICS, CORP in JUNO BEACH, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,617,999. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.